Akero Therapeutics (AKRO) EGM 2025 summary

Opening remarks and agenda

• Meeting called to order at 11:00 A.M. Eastern Time, with rules of conduct posted on the web portal.

• Inspector of Election appointed and oath filed with meeting minutes.

• Notice, proxy statement, and affidavit of mailing made available to all stockholders.

• Quorum confirmed with majority of outstanding shares present or represented by proxy.

Specific resolutions to be voted on

• Adoption of the Agreement and Plan of Merger with Novo Nordisk A/S and NN Invest Sub Incorporated, including a Contingent Value Rights agreement.

• Advisory non-binding approval of compensation to named executive officers in connection with the merger.

Overview of voting outcomes

• Merger proposal approved by majority of outstanding shares.

• Compensation proposal also approved by majority of outstanding shares.

• Adjournment proposal not presented as merger was approved.